Advancing Treatment of
Bladder Cancer
A Continuing Medical Education Activity sponsored by InforMEDical Communications, Inc.
InforMEDical Communications, Inc. •
83 Acton Street • Carlisle, MA 01741
tel: 978-318-9582 • fax: 978-318-9583 • email: info@informedicalcme.com
Introduction
Bladder cancer is the fifth most common malignancy, with an estimated 67,000 newly diagnosed cases and 13,000 deaths in the United States in 20071. Approximately 75% of patients present with superficial disease and are managed primarily by urologists with cystoscopy and transurethral resection (TUR) with or without intravesicular therapy, depending on tumor grade, presence of carcinoma in situ (CIS), and depth of invasion. The remaining patients, approximately 25%, have muscle-invasive disease evident on a biopsy specimen and have a worse prognosis. Outcomes in these patients are dependent on tumor stage and grade. High relapse rates are seen even with disease confined to the bladder wall managed with cystectomy or primary radiotherapy. Patients who subsequently develop or present with metastatic disease can expect a median survival time of approximately 14 months when treated with combination systemic chemotherapy.
This educational activity has been developed to provide an overview of recent progress and challenges in treating patients with superficial and muscle-invasive disease. It is intended to provide a framework for assessing the appropriate use of systemic chemotherapy in the management of muscle-invasive bladder cancer and optimal approaches to treating superficial bladder cancer. Register now to receive up to 3 AMA PRA Category 1 credits for completing this CME activity.
Program Faculty
Colin P. N. Dinney, MD
Professor and Chairman, Department of Urology
Professor, Department of Cancer Biology
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas
Maha Hussain, MD, FACP
Professor of Medicine & Urology
University of Michigan
Comprehensive Cancer Center
Ann Arbor, Michigan
This CME activity is supported by educational grants from
Schering Plough, Bristol-Myers Squibb and Eli Lilly.